PuSH - Publikationsserver des Helmholtz Zentrums München

44 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
Alle Publikationen dieser Seite in den Korb legen
1.
Haffner, I.* et al.: Treatment of HER2 positive advanced gastric cancer: Deviations in HER2 results and its impact on survival. Oncol. Res. Treat. 43, 65-65 (2020)
2.
Cheney, C.P. et al.: The association between serum 25-Hydroxyvitamin D and cancer risk: Results from the prospective KORA F4 study. Oncol. Res. Treat. 41, 117-121 (2018)
3.
Haffner, I.* et al.: Determination of HER2 in Gastric Cancer (GC) is still challenging: high deviation rates between local and central pathologies and its impact on survival. Oncol. Res. Treat. 41, 240-240 (2018)
4.
Pfirrmann, M.* et al.: The EUTOS long-term survival (ELTS) score is superior to the Sokal score for prognosis of probabilities of dying of chronicphase chronic myeloid leukaemia. Oncol. Res. Treat. 41, 140-141 (2018)
5.
Eichner, R.* et al.: Immunomodulatory drugs destabilize CD98hc and LAT1 to interfere with amino acid transport and tumor metabolism. Oncol. Res. Treat. 40, 82-82 (2017)
6.
Gary, R.* et al.: Adoptive transfer of CMV- and EBV-specific peptide-stimulated T cells after allogeneic stem cell transplantation: First results of a phase I/IIa clinical trial [AIT-MULTIVIR-01]. Oncol. Res. Treat. 40, 239-239 (2017)
7.
Habringer, S.* et al.: CXCR4-directed peptide receptor radiotherapy with 177Lu-Pentixather effectively clears leukemia in patient-derived xenografts. Oncol. Res. Treat. 40, 214-214 (2017)
8.
Jacobs, L.A.* et al.: A study of Myc-regulated metabolic changes in transformed B cells. Oncol. Res. Treat. 40, 218-218 (2017)
9.
Krupka, C. et al.: Influence of cytoreductive and immunmodulatory drugs on antibody-based approaches in AML. Oncol. Res. Treat. 40, 84-85 (2017)
10.
Lichtenegger, F.S. et al.: Induction of antigen-specific T-cell responses through dendritic cell vaccination in AML: Results of a phase I/II trial and ex vivo enhancement by checkpoint blockade. Oncol. Res. Treat. 40, 135-135 (2017)
11.
Richter, A.S.* et al.: CK2 inhibition reduces cell proliferation in acute B-lymphoblastic leukemia cells in vitro and in vivo. Oncol. Res. Treat. 40, 20-20 (2017)
12.
Friemel, I.* et al.: Intratumor heterogeneity in hepatocellular carcinoma: Impact on tumor classifications and targeted therapies. Oncol. Res. Treat. 39, 81 (2016)
13.
Gross, E.* et al.: Validation of a BRCAness test to select for targeted therapies in triple-negative breast cancer. Oncol. Res. Treat. 39, 54 (2016)
14.
Habringer, S.* et al.: CXCR4-directed peptide receptor radiotherapy with 177Lu-Pentixather effectively clears leukemia in patient-derived xenografts. Oncol. Res. Treat. 39, 214-214 (2016)
15.
Haffner, I.* et al.: Clinical validation of response and resistance factor candidates to targeted therapy in Gastric Cancer (GC). Oncol. Res. Treat. 39, 16-17 (2016)
16.
Jacobs, L.A.* et al.: A study of Myc-regulated metabolic changes in transformed B cells. Oncol. Res. Treat. 39, 218-218 (2016)
17.
Krupka, C. et al.: Influence of cytoreductive and immunmodulatory drugs on antibody-based approaches in AML. Oncol. Res. Treat. 39, 84-85 (2016)
18.
Lichtenedger, F.S. et al.: Induction of antigen-specific T-cell responses through dendritic cell vaccination in AML: results of a phase I/II trial and ex vivo enhancement by checkpoint blockade. Oncol. Res. Treat. 39, 135-135 (2016)
19.
Neff, F.* et al.: Targeting notch for myeloid reprogramming in pancreatic cancer. Oncol. Res. Treat. 39, 16 (2016)
20.
Trajkovic-Arsic, M.* et al.: Identification of metabolic changes in pancreatic ductal adenocarcinoma. Oncol. Res. Treat. 39, 76-77 (2016)